
MIT, in collaboration with the Commonwealth of Massachusetts, announced plans to establish the Quantum Systems Laboratory (QSL) at MIT. This new facility will serve as a regional hub for quantum research, providing advanced infrastructure for scientists to explore quantum technologies. With a $25 million investment from the state, matched by federal funding, the QSL aims to accelerate innovation in fields such as life sciences and defense. The initiative is expected to bolster Massachusetts' position as a leader in quantum technology, creating jobs and supporting startups in the process.
Read original
© TechCrunch AIRecursive self-improvement (RSI) is emerging as a buzzword in AI, akin to the earlier hype around AGI. The concept involves AI systems that can autonomously upgrade themselves, potentially leading to rapid advancements limited only by available compute power. Notable figures like Richard Socher and Andrej Karpathy are actively pursuing RSI, with projects like Auto-Research and AutoScientist aiming to automate AI research processes. While the industry is not yet close to achieving full RSI, the pursuit is driving significant interest and investment, hinting at a future where AI could independently push its own boundaries.
© NVIDIA BlogNVIDIA's latest research is pushing the boundaries of robotics by enhancing the transition from simulation to real-world applications. At the ICRA conference, NVIDIA showcased eight papers that highlight advancements in robotic perception, reasoning, and action across unpredictable environments. These innovations include multi-arm coordination, adaptive grasping, and navigation across diverse robot bodies, all trained in simulation without real-world data. This approach not only speeds up robotic processes but also improves success rates significantly, marking a step forward in creating adaptable and reliable autonomous robots.
© The Rundown AIBiohub, backed by Mark Zuckerberg and Priscilla Chan, has unveiled a groundbreaking open-source model for protein biology. This 'world model' aims to accelerate drug discovery by predicting and designing proteins, potentially reducing the time from years to months. The model, ESMFold2, claims state-of-the-art performance in protein structure prediction, surpassing even AlphaFold. It has already shown promising results in designing binders for cancer and immune disease targets. This release could democratize access to advanced molecular tools, empowering researchers worldwide to tackle diseases more effectively.